Back to Search
STEPHEN HANAUER, MD
MD
Gastroenterology Physician
NPI: 1992868418IndividualAccepts Medicare
Specialties, Licenses & Credentials
Gastroenterology PhysicianPrimary
Internal Medicine — Gastroenterology
Code: 207RG0100X
036057399(IL)
Education
UNIVERSITY OF MICHIGAN MEDICAL SCHOOL
Class of 1973
Research & Publications (20)
Positioning biologic agents in the treatment of Crohn's disease.
PMID 19309716·Inflamm Bowel Dis·2009
6-review
Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
PMID 18307645·Aliment Pharmacol Ther·2008
6-review
The role of loperamide in gastrointestinal disorders.
PMID 18477966·Rev Gastroenterol Disord·2008
6-review
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
PMID 18080055·Can J Gastroenterol·2007
4-observational
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
PMID 17698862·Gut·2007
8-other
The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction.
PMID 18192960·Rev Gastroenterol Disord·2007
8-other
Refining the role of TNF antagonists for Crohn's disease. Introduction.
PMID 17392632·Rev Gastroenterol Disord·2007
8-other
Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down".
PMID 17392635·Rev Gastroenterol Disord·2007
6-review
Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort.
PMID 17519069·Curr Med Res Opin·2007
4-observational
New lessons: classic treatments, expanding options in ulcerative colitis.
PMID 16594960·Colorectal Dis·2006
6-review
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
PMID 16472588·Gastroenterology·2006
4-observational
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.
PMID 16378007·Inflamm Bowel Dis·2006
6-review
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
PMID 16961743·Aliment Pharmacol Ther·2006
6-review
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
PMID 16279903·Am J Gastroenterol·2005
4-observational
The case for using 5-aminosalicyclates in Crohn's disease: pro.
PMID 15905710·Inflamm Bowel Dis·2005
8-other
Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
PMID 15984961·Am J Gastroenterol·2005
8-other
Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
PMID 15709986·Aliment Pharmacol Ther·2005
3-trial
Update on the etiology, pathogenesis and diagnosis of ulcerative colitis.
PMID 16265041·Nat Clin Pract Gastroenterol Hepatol·2004
6-review
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.
PMID 15580149·Rev Gastroenterol Disord·2004
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 676 N SAINT CLAIR ST STE 650
CHICAGO, IL 60611 - Phone
- (312) 695-5620
Quick Facts
- NPI
- 1992868418
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 53
- Publications
- 20
Are you this provider?
Claim Your Profile